Literature DB >> 15013884

Intraocular availability of triamcinolone acetonide after intravitreal injection.

Jost B Jonas1.   

Abstract

BACKGROUND: To evaluate the intraocular concentration of triamcinolone acetonide after intravitreal injection.
METHODS: The prospective clinical interventional case series study included 17 patients who had received a 20 to 25-mg intravitreal injection of triamcinolone acetonide as treatment for exudative age-related macular degeneration, diffuse diabetic macular edema, or retinal vein occlusions. During a secondary intraocular surgery taking place 4.1 weeks to 25.7 months after the intravitreal injection, aqueous humor samples were obtained. None of the eyes were vitrectomized.
RESULTS: In the aqueous humor samples, triamcinolone acetonide was in low, but measurable, concentrations detected up to 1.5 years after the intravitreal injection. Concentrations found in samples obtained during the first 6 months, or 7 to 12 months, respectively, after the injection ranged between 3.0 microg/l and 436 microg/l, and between 0.0 microg/l and 11.2 microg/l, respectively.
CONCLUSIONS: After injection of triamcinolone acetonide, triamcinolone can be present in measurable concentrations up to 1.5 years after the application.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013884     DOI: 10.1016/j.ajo.2003.08.012

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  24 in total

1.  Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; R F Degenring
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

2.  Viral retinitis after intravitreal triamcinolone injection in patients with predisposing medical comorbidities.

Authors:  Ankur M Shah; Stephen F Oster; William R Freeman
Journal:  Am J Ophthalmol       Date:  2010-03       Impact factor: 5.258

3.  The problem of pressure elevation associated with intravitreal triamcinolone.

Authors:  M D Conway
Journal:  Br J Ophthalmol       Date:  2006-08       Impact factor: 4.638

4.  Influence of different purification techniques on triamcinolone yield and particle size spectrum.

Authors:  Peter Szurman; Radoslaw Kaczmarek; Gesine B Jaissle; Salvatore Grisanti; Matthias Lüke; Martin S Spitzer; Peter-Edgar Heide; Karl U Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-09-28       Impact factor: 3.117

5.  Cytomegalovirus retinitis after intravitreal triamcinolone acetonide in an immunocompetent patient.

Authors:  Sekiryu Tetsuju; Tomohiro Iida; Hisatoshi Kaneko; Masaaki Saito
Journal:  Jpn J Ophthalmol       Date:  2008-11-11       Impact factor: 2.447

6.  Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.

Authors:  A M Tammewar; L Cheng; O R Kayikcioglu; I A Falkenstein; I Kozak; M H Goldbaum; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-04-17       Impact factor: 4.638

7.  Intravitreal triamcinolone acetonide: Pattern of secondary intraocular pressure rise and possible risk factors.

Authors:  Ziad F Bashshur; Abdallah M Terro; Christelle P El Haibi; Akaber M Halawi; Alexandre Schakal; Baha' N Noureddin
Journal:  Clin Ophthalmol       Date:  2008-06

8.  Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone.

Authors:  M Selim Kocabora; Cemil Yilmazli; Muhittin Taskapili; Gokhan Gulkilik; Sahan Durmaz
Journal:  Clin Ophthalmol       Date:  2008-03

9.  Intravitreal triamcinolone reinjection for refractory diabetic macular edema.

Authors:  Alireza Ramezani; Hamid Ahmadieh; Homa Tabatabaei
Journal:  Korean J Ophthalmol       Date:  2006-09

10.  [Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD].

Authors:  A Frimpong-Boateng; M A Varde; F Rüfer; A Bunse; J Roider
Journal:  Ophthalmologe       Date:  2008-07       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.